Colorectal Cancer Biomarkers: Where Are We Now?

Table 3

Summary of conventional and innovative CRC molecular diagnostic and screening methods.

	Sensitivity (%)	Specificity (%)	Status
Tumor
IHC	83	90	In use
MSI	55–91	90	In use
CIMP	N/A	N/A	Under evaluation
Stool
gFOBT	11–64	91–98	In use
iFOBT	56–89	91–97	In use
Vimentin	72.5–83	53–86.9	In use
Multitarget stool test	42.4 (advanced adenomas); 92.3 (CRC)	986.6	Clinical validation
Blood
CEA	30–63	63–100	In use
CA 19-9	18–52	79–100	In use
TIMP-1	55	95	Clinical validation
CTCs	32–94	ND- 94	Clinical validation

For diagnosis of Lynch Syndrome [68]. ND: not determined; N/A: not applicable. [69], [70], and [71].